Market Cap 366.37M
Revenue (ttm) 12.14M
Net Income (ttm) -99.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -819.60%
Debt to Equity Ratio 0.00
Volume 288,700
Avg Vol 431,336
Day's Range N/A - N/A
Shares Out 79.65M
Stochastic %K 45%
Beta 0.95
Analysts Strong Sell
Price Target $8.00

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat M...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 467 1280
Address:
175 Innovation Boulevard, Wilmington, United States
tiddyy
tiddyy Aug. 4 at 12:48 PM
$PRLD I am so tempted to buy this, but this is so high already. Only thing is OrbiMed purchased some shares, and Baker Bros got a lot of options purchased around the $4 price This looks really interesting, also the Incyte deal. I want to get in so bad but I would prefer to get in the $3
0 · Reply
LSOTradingDesk
LSOTradingDesk Jul. 31 at 10:54 AM
$PGEN and $PRLD 🤔
0 · Reply
TwinTurboBul161
TwinTurboBul161 Jul. 30 at 9:35 PM
0 · Reply
LabPsycho
LabPsycho Jul. 30 at 8:22 PM
$PRLD I get the feeling this place is just outsourcing all their R&D. I can not seem to find any of their structures. Why do they bother publishing something like this where their molecule is represented as a circle - thats not a good look of competence IMO.
1 · Reply
elitechrisvp
elitechrisvp Jul. 30 at 7:37 PM
$PRLD looking good! ✅️👍
0 · Reply
KUMO2026
KUMO2026 Jul. 30 at 1:58 PM
$PRLD 5.06 swing exit
1 · Reply
topstockalerts
topstockalerts Jul. 28 at 9:32 PM
$PRLD this chart has become surprisingly hard to argue with.
0 · Reply
prismmarketview
prismmarketview Jul. 28 at 5:07 PM
PRISM Mid-Day Movers: MedTech and BioTech are Todays Leaders. Accuray Incorporated (NASDAQ: $ARAY ) is jumping today, with the stock up about 12% to 0.2529 from a prior close of 0.225. Prelude Therapeutics Incorporated (NASDAQ: $PRLD ) is up today, with the stock rising about 12% to 4.34 from a prior close of 3.89. Other Notable Movers: http://Gambling.com Group ( $GAMB) up 10% Bitfarms (NASDAQ: $BITF) up 9% SunPower Corporation ( $SPWR ) down -22% https://prismmarketview.com/prism-mid-day-movers-medtech-and-biotech-are-todays-leaders/ Disclaimer: Stock prices are shown as of a specific point in time: 7/27/27 at 12:50 PM. Prices may have changed since then, and real-time market values may differ.
0 · Reply
notreload_ai
notreload_ai Jul. 28 at 5:05 PM
$PRLD stock rises after $INCY discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal. https://notreload.xyz/xy/prelude-shares-jump-as-incyte-drops-rival-jak2-drug/
1 · Reply
PennySearch
PennySearch Jul. 28 at 3:33 PM
📈 Top Penny Stock Movers by Relative Volume $POLA — 24.14x RVOL Move: +30% Volume: 39.8M (1.6M average) Market Cap: $5.3M Day Range: 1.69 – 2.36 52-Week Range: 1.31 – 5.75 $PRLD — 1.89x RVOL Move: +17% Volume: 961.2K (507.8K average) Market Cap: $260.2M Day Range: 4.19 – 4.85 52-Week Range: 0.75 – 5.69 $BZFD — 1.88x RVOL Move: +8% Volume: 1.7M (887.3K average) Market Cap: $46.3M Day Range: 1.17 – 1.26 52-Week Range: 0.54 – 2.43 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
0 · Reply
Latest News on PRLD
Prelude Therapeutics Transcript: AGM 2026

Jun 9, 2026, 8:30 AM EDT - 2 months ago

Prelude Therapeutics Transcript: AGM 2026


Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

2026-05-12T11:55:16.000Z - 3 months ago

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)


Prelude Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Earnings release: Q1 2026


Prelude Therapeutics Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Quarterly report: Q1 2026


Prelude Therapeutics Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Slides: Corporate presentation


Prelude Therapeutics initiated with a Buy at D. Boral Capital

2026-05-04T11:35:31.000Z - 3 months ago

Prelude Therapeutics initiated with a Buy at D. Boral Capital


Prelude Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Prelude Therapeutics Proxy statement: Proxy filing


Prelude Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Prelude Therapeutics Proxy statement: Proxy filing


Prelude Therapeutics Slides: Corporate presentation

Apr 20, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Slides: Corporate presentation


Prelude Therapeutics management to meet with Citizens

2026-03-18T18:55:15.000Z - 4 months ago

Prelude Therapeutics management to meet with Citizens


Prelude Therapeutics Transcript: Conference

Mar 10, 2026, 3:25 PM EDT - 5 months ago

Prelude Therapeutics Transcript: Conference


Prelude Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Prelude Therapeutics Annual report: Q4 2025


Prelude Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Prelude Therapeutics Earnings release: Q4 2025


Prelude Therapeutics sees cash runway into 2Q27

2026-03-10T11:10:14.000Z - 5 months ago

Prelude Therapeutics sees cash runway into 2Q27


Prelude Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Prelude Therapeutics Slides: Corporate presentation


Prelude Therapeutics Registration statement: Registration Filing

Dec 10, 2025, 7:00 AM EST - 8 months ago

Prelude Therapeutics Registration statement: Registration Filing


Prelude Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prelude Therapeutics Earnings Call Transcript: Q3 2025


Prelude Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prelude Therapeutics Quarterly report: Q3 2025


Prelude Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Prelude Therapeutics Earnings release: Q3 2025


Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year

2025-11-12T12:22:24.000Z - 9 months ago

Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year


Prelude Therapeutics sees cash runway into 2027

2025-11-12T12:22:00.000Z - 9 months ago

Prelude Therapeutics sees cash runway into 2027


Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:05 AM EST - 9 months ago

Prelude Therapeutics Announces Strategic Business Update


Prelude Therapeutics Slides: Corporate Presentation

Nov 3, 2025, 7:00 AM EST - 9 months ago

Prelude Therapeutics Slides: Corporate Presentation


Prelude Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Quarterly report: Q2 2025


Prelude Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q2 2025


Prelude Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Quarterly report: Q1 2025


Prelude Therapeutics Earnings release: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q1 2025


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 1 year ago

Prelude Announces Presentations at 2025 AACR Annual Meeting


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Annual report: Q4 2024

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Annual report: Q4 2024


Prelude Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q4 2024


Prelude Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Quarterly report: Q3 2024


Prelude Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Earnings release: Q3 2024


Prelude Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Study Update


Prelude Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Press release: Study Update


Prelude Therapeutics Slides: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Slides: Study Update


Prelude Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q2 2024


Prelude Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q2 2024


Prelude Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q1 2024


Prelude Therapeutics Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q1 2024


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Annual report: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Annual report: Q4 2023


Prelude Therapeutics Earnings release: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Earnings release: Q4 2023


Prelude Therapeutics Announces $25 Million Private Placement

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement


Prelude Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 4:00 PM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q3 2023


Prelude Therapeutics Earnings release: Q3 2023

Nov 1, 2023, 4:00 PM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q3 2023


Prelude Therapeutics Quarterly report: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q2 2023


Prelude Therapeutics Earnings release: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q2 2023


Prelude Therapeutics Quarterly report: Q1 2023

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q1 2023


Prelude Therapeutics Earnings release: Q1 2023

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q1 2023


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Proxy statement: Proxy Filing

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing


Prelude Therapeutics Annual report: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Annual report: Q4 2022


Prelude Therapeutics Earnings release: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q4 2022


tiddyy
tiddyy Aug. 4 at 12:48 PM
$PRLD I am so tempted to buy this, but this is so high already. Only thing is OrbiMed purchased some shares, and Baker Bros got a lot of options purchased around the $4 price This looks really interesting, also the Incyte deal. I want to get in so bad but I would prefer to get in the $3
0 · Reply
LSOTradingDesk
LSOTradingDesk Jul. 31 at 10:54 AM
$PGEN and $PRLD 🤔
0 · Reply
TwinTurboBul161
TwinTurboBul161 Jul. 30 at 9:35 PM
0 · Reply
LabPsycho
LabPsycho Jul. 30 at 8:22 PM
$PRLD I get the feeling this place is just outsourcing all their R&D. I can not seem to find any of their structures. Why do they bother publishing something like this where their molecule is represented as a circle - thats not a good look of competence IMO.
1 · Reply
elitechrisvp
elitechrisvp Jul. 30 at 7:37 PM
$PRLD looking good! ✅️👍
0 · Reply
KUMO2026
KUMO2026 Jul. 30 at 1:58 PM
$PRLD 5.06 swing exit
1 · Reply
topstockalerts
topstockalerts Jul. 28 at 9:32 PM
$PRLD this chart has become surprisingly hard to argue with.
0 · Reply
prismmarketview
prismmarketview Jul. 28 at 5:07 PM
PRISM Mid-Day Movers: MedTech and BioTech are Todays Leaders. Accuray Incorporated (NASDAQ: $ARAY ) is jumping today, with the stock up about 12% to 0.2529 from a prior close of 0.225. Prelude Therapeutics Incorporated (NASDAQ: $PRLD ) is up today, with the stock rising about 12% to 4.34 from a prior close of 3.89. Other Notable Movers: http://Gambling.com Group ( $GAMB) up 10% Bitfarms (NASDAQ: $BITF) up 9% SunPower Corporation ( $SPWR ) down -22% https://prismmarketview.com/prism-mid-day-movers-medtech-and-biotech-are-todays-leaders/ Disclaimer: Stock prices are shown as of a specific point in time: 7/27/27 at 12:50 PM. Prices may have changed since then, and real-time market values may differ.
0 · Reply
notreload_ai
notreload_ai Jul. 28 at 5:05 PM
$PRLD stock rises after $INCY discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal. https://notreload.xyz/xy/prelude-shares-jump-as-incyte-drops-rival-jak2-drug/
1 · Reply
PennySearch
PennySearch Jul. 28 at 3:33 PM
📈 Top Penny Stock Movers by Relative Volume $POLA — 24.14x RVOL Move: +30% Volume: 39.8M (1.6M average) Market Cap: $5.3M Day Range: 1.69 – 2.36 52-Week Range: 1.31 – 5.75 $PRLD — 1.89x RVOL Move: +17% Volume: 961.2K (507.8K average) Market Cap: $260.2M Day Range: 4.19 – 4.85 52-Week Range: 0.75 – 5.69 $BZFD — 1.88x RVOL Move: +8% Volume: 1.7M (887.3K average) Market Cap: $46.3M Day Range: 1.17 – 1.26 52-Week Range: 0.54 – 2.43 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 3:02 PM
Top Gainers PT2 $POLA $FIRY $OPK $OMH $PRLD
0 · Reply
LeoWhite961
LeoWhite961 Jul. 28 at 2:51 PM
$INCY is dropping its JAK2 V617F inhibitor INCB160058 and shifting capital toward its next-gen pipeline. That leaves room for programs like $PRLD’s PRT12396, which Incyte already has an option on from last year.
0 · Reply
r_ChartLaboratory
r_ChartLaboratory Jul. 28 at 2:26 PM
Intraday Top 5 Bullish Plays — July 28, 2026 $POLA is leading the session after Polar Power announced a committed equity facility with Roth Principal Investments. The funding is intended to support working capital and expand its DC power systems business into data centers, drone charging, and EV applications. $OPK is moving higher following second-quarter results that showed solid revenue and a narrowed net loss. The company also raised its full-year revenue guidance. $BKYI continues to attract interest after the Central Bank of Jordan selected BIO-key for a national biometric authentication initiative across the country’s financial sector. The project aims to advance passwordless biometric solutions for a large population. $PRLD is showing strength on elevated relative volume in the biotechnology space, with the move occurring without a major company-specific announcement in the most recent sessions. $RITM is grinding higher after Rithm Capital reported second-quarter results
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 28 at 2:00 PM
$CNET $POLA $OMH $PRLD $WBUY keeping eye
0 · Reply
KUMO2026
KUMO2026 Jul. 28 at 1:57 PM
$PRLD swing trade to 5.30
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 1:34 PM
$PMN Webinar: Plasma pTau217: After 169 days, 68.5% of all patients showed a clear reduction in harmful proteins to levels below their baseline. The average reduction across all participants was 15%. This stands in direct contrast to untreated patients, in whom this value steadily rises as the disease progresses. CSF MTBR-tau243 : 62.5% of all patients exhibited a measurable reduction in tau-tangle-specific proteins. The average reduction in cerebrospinal fluid was 13.3%. Since this marker represents insoluble fibers, any decrease in the cerebrospinal fluid is considered a strong indicator that the degeneration of brain cells is slowing down. Note for interpretation: The fact that the responder rates (68.5% and 62.5%) are strikingly close to the actual drug-to-placebo distribution of 75% (based on the 3:1 study design) provides extremely strong mathematical evidence that the cases of deterioration are almost exclusively attributable to the placebo patients. $BIYA $OMH $PRLD $RECT
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 1:02 PM
Pre Market Top Gainers PT2 $OMH $PRLD $BIYA $PMN $RECT
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 12:16 PM
Pre Market Top Gainers PT2 $OMH $PRLD $BIYA $PMN $RECT
0 · Reply
PatrickandFrankie
PatrickandFrankie Jul. 28 at 11:48 AM
$PRLD newly disclosed institutional investor Ecor owns close to 1m shares
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 28 at 11:19 AM
$PRLD thin
0 · Reply
LabPsycho
LabPsycho Jul. 20 at 3:32 PM
$PRLD @exp8triot Seems like another vacuous bot article
0 · Reply
exp8triot
exp8triot Jul. 18 at 5:43 PM
$PRLD upgraded to buy rating https://finance.yahoo.com/markets/stocks/articles/prelude-therapeutics-prld-upgraded-buy-160005763.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJWIv-wBpl8aXkp_wfocNoSbjORxSp55hdkpLmwwTRp1R4yA95iW0O4Evg1pDM-qMhbz1jC90rG9-vjHCXMJSOwV4qEb7ngaF27emYpt_34fOUMe0s5T45Vi9ORhjsZrFJxVHHuaFYa3nJXYr90rGEKmgPaJjDcMPvjZO0DUtmRQ
0 · Reply